(Q30442049)

21 June 2017

title

Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas (English)

1 reference

21 June 2017

1 reference

1

Nader Pouratian

0 references

author name string

Jaime Gasco

2

1 reference

21 June 2017

Jonathan H Sherman

3

1 reference

21 June 2017

Mark E Shaffrey

4

1 reference

21 June 2017

David Schiff

5

1 reference

21 June 2017

publication date

3 November 2006

1 reference

Journal of Neuro-Oncology

21 June 2017

published in

1 reference

21 June 2017

volume

82

1 reference

21 June 2017

issue

3

1 reference

21 June 2017

page(s)

281-288

1 reference

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 June 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-006-9280-4

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-006-9280-4

Extended continuous oral temozolomide in patients with progressive metastatic renal cell carcinoma not responding to interferon alpha 2b.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-006-9280-4

O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells

21 January 2018

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas

1 reference

12 December 2020

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

12 December 2020

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

1 reference

12 December 2020

O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study

1 reference

12 December 2020

Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression

1 reference

12 December 2020

Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response

1 reference

12 December 2020

Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.

1 reference

12 December 2020

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

1 reference

12 December 2020

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

1 reference

12 December 2020

Is protracted low-dose temozolomide feasible in glioma patients?

1 reference

12 December 2020

Current and future trials of the EORTC brain tumor group

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents

1 reference

12 December 2020

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

1 reference

12 December 2020

Clinical relevance of MGMT in the treatment of cancer

1 reference

12 December 2020

Phase II trial of temozolomide in patients with progressive low-grade glioma

1 reference

12 December 2020

Phase I trial of temozolomide using an extended continuous oral schedule.

1 reference

12 December 2020

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine

1 reference

12 December 2020

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

1 reference

12 December 2020

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

12 December 2020

Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.

1 reference

12 December 2020

O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy

1 reference

12 December 2020

Response of low-grade oligodendroglial tumors to temozolomide

1 reference

12 December 2020

Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis

1 reference

12 December 2020

O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines

1 reference

12 December 2020

10.1007/S11060-006-9280-4

Identifiers

DOI

1 reference

Dimensions Publication ID

21 June 2017

1036852543

0 references

1 reference